The Japanese drugmaker that sells rare-disease medicine Tavneos said new patients will be able to get the drug, which carries risk of liver injury.

After the FDA flagged patient deaths linked to Amgen's rare disease drug Tavneos and called for its voluntary removal, the ...

Twenty people died in Japan after receiving Tavneos, a rare disorder therapy developed by Amgen (AMGN), prompting its local partner Kissei (KSPHF) to urge healthcare professionals to exercise caution ...

Kissei Pharmaceutical, which sells the rare immune-disease drug in Japan, warned doctors to stop prescribing it to new patients.

A Japanese pharmaceutical firm has warned doctors against prescribing a drug for rare autoimmune diseases to new patients following the deaths of 20 people who took it. Kissei Pharmaceutical, which ...

Amgen is standing behind a rare disease drug that the FDA wants off the market due to safety concerns and alleged clinical trial manipulation, and its defense will include a new analysis of the ...

An independent research firm is reviewing data on Amgen’s Tavneos as the company prepares for a hearing with the FDA which ...

April 27 (Reuters) - The U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER) has proposed withdrawing approval of Amgen's (AMGN.O), opens new tab drug for rare ...

Kissei Pharmaceutical has revised a package insert in Japan for Amgen's rare immune-disease drug Tavneos, saying that serious liver dysfunction could occur. The Japanese pharmaceutical company said ...

Japanese drugmaker Kissei Pharmaceutical 45470.53%increase; up pointing triangle said doctors in Japan can again prescribe an Amgen AMGN 1.15%increase; up pointing triangle rare-disease drug to new ...